PDCD1 and non-small cell lung carcinoma: For example, two anti-PD-1 therapies (nivolumab and pembrolizumab) and one anti-PD-L1 agent (atezolizumab) are in the advanced stages of development as treatments for advanced or metastatic NSCLC [65].